Biotechnology

Lundbeck announces last patient randomized in DEEp OCEAN, a large Phase III trial in developmental and epileptic encephalopathies (DEEs)

* DEEp OCEAN is a global trial designed to evaluate the investigational molecule bexicaserin for the treatment of seizures associated with DEEs, a diverse group of childhood-onset epilepsies1 * Broadest pivotal trial to date, enrolling patients with a wide range of DEE syndromes, the majority...

2026-07-20 16:20

Medtrum Advances 300U Tubeless Patch Pump Toward German Launch

Higher-capacity option expands the TouchCare Nano System and supports Medtrum's continued growth in Europe BERLIN, July 20, 2026 /PRNewswire/ -- Medtrum, a global diabetes technology company, today announced further progress toward the German launch of its 300-unit (300U) tubeless patch pump, fo...

2026-07-20 15:05 314

Antengene Announces Poster Presentation of ATG-022 and ATG-037 at ESMO 2026

SHANGHAI and HONG KONG, July 20, 2026 /PRNewswire/ -- Antengene Corporation Limited ("Antengene", SEHK: 6996.HK), a leading innovative, commercial-stage global biotech company dedicated to discovering, developing and commercializing first-in-class and/or best-in-class medicines for autoimmune dis...

2026-07-20 15:00 365

Fostering new opportunities in the Greater Bay Area and Asia's Pharmaceutical Industry

SHANGHAI, July 20, 2026 /PRNewswire/ -- Following the landmark success of CPHI & PMEC China in June 2026, which welcomed an unprecedented gathering of industry professionals and fostered pivotal connections across the pharmaceutical supply chain, attention now shifts to South China. Building on ...

2026-07-20 12:52 959

NYSE Content Update: AdvanCell Raises $315 Million to Fight Prostate Cancer

NYSE issues a pre-market daily advisory direct from the trading floor. NEW YORK, July 17, 2026 /PRNewswire/ -- The New York Stock Exchange (NYSE) provides a daily pre-market update directly from the NYSE Trading Floor. Access today's NYSE Pre-market update for market insights before trading begin...

2026-07-17 20:56 4241

Getinge Interim Report April-June 2026: Good organic growth, high profitability and strong cash flow

GOTHENBURG, Sweden, July 17, 2026 /PRNewswire/ --  "We delivered a strong quarter both financially and operationally with several important key achievements," says Mattias Perjos, President and CEO of Getinge. Sales in Acute Care Therapies increased in most product categories, and the positive ...

2026-07-17 14:45 2277

Creative Life Science Advances PIC/S GMP-Compliant Cell Therapy Materials and Manufacturing Platform

Targets Japan and Singapore as Part of Broader Asia Expansion TAIPEI, July 17, 2026 /PRNewswire/ -- BIO Asia-Taiwan 2026 opens July 16 at the Taipei Nangang Exhibition Center and runs through July 19. Creative Life Science (7837) is showcasing its upstream regenerative medicine materials, proces...

2026-07-17 14:12 2511

The HKIC Presents Stellar Annual Report and Joins Hands with Beyond Ventures to Support World-Class Ophthalmic Healthcare Flagship Projects

"Patient Capital" Nurtures Life Science Innovations: MingMed and Super Vision Featured as Selected Investment Stories in the HKIC's Annual Report HONG KONG, July 17, 2026 /PRNewswire/ -- Beyond Ventures, a Hong Kong-based venture capital firm, warmly congratulates the Hong Kong Investment Corpora...

2026-07-17 09:14 3479

Telix Completes Patient Enrollment in TLX591-Px (Illuccix®) Japan Phase 3 Study

* Completed enrollment of 105 patients in Phase 3 registration study of TLX591-Px (Illuccix®) for prostate cancer imaging in Japan. * The study data will be used to support a New Drug Application (NDA) for TLX591-Px in Japan. MELBOURNE, Australia and TOKYO, July 17, 2026 /PRNewswire/ -- Telix...

2026-07-17 06:00 3107

Angel Yeast Showcases Sustainable Protein Innovation at the Growth Asia Summit 2026

SHANGHAI, July 16, 2026 /PRNewswire/ -- Angel Yeast (SSE: 600298) showcased its latest yeast protein innovations at the Growth Asia Summit 2026 in Singapore, held from July 8 to 10. On the second day — dedicated to Active Lifestyles, Weight Management, Protein and Heal...

2026-07-16 16:22 2648

Novonesis and TurtleTree enter partnership to support commercialization of lactoferrin

COPENHAGEN, Denmark, July 16, 2026 /PRNewswire/ -- Novonesis, a global leader in biosolutions, today announced an agreement with TurtleTree, an innovator in precision fermented ingredients, and the first company to receive a US GRAS "No Objection Letter" for its precision fermented lactoferrin LF...

2026-07-16 09:00 2293

Telix Opens Australian-First Facility to Accelerate Delivery of New Cancer Treatments and Expand Sovereign Manufacturing

* First-of-its-kind facility in Australia where radiopharmaceuticals are developed, manufactured and administered to patients under one roof. * Patient care and research delivered in collaboration with the Melbourne Theranostic Innovation Centre (MTIC), led by its world-class clinical research...

2026-07-16 08:30 3540

First Patients Dosed in OPTIMAL-e Trial for Earlier Stage Prostate Cancer

* First patients dosed in OPTIMAL-e[1] Phase 2 study evaluating TLX597-Tx for metastatic hormone-sensitive prostate cancer at St Vincent's Hospital Sydney. * OPTIMAL-e will evaluate TLX597-Tx in earlier prostate cancer treatment setting, building on the OPTIMAL-PSMA[2] study which recently com...

2026-07-16 04:30 2922

Metabolon Expands Microbiome Panel to Strengthen Industry Leadership in Functional Microbiome Research

Enhanced panel screens for more than 800 microbiome-associated metabolites, giving researchers a broader view of microbial activity linked to human health, nutrition, disease, and treatment response MORRISVILLE, N.C., July 15, 2026 /PRNewswire/ -- Metabolon, Inc., the global leader in metabolomi...

2026-07-15 21:00 4212

Ascletis Selects for Clinical Development a Fixed-Dose Combination of First-in-Class Oral Small Molecule GIPR Agonist, ASC48, and Oral Small Molecule GLP-1R Agonist, ASC30

- ASC48 is a potentially first-in-class oral small molecule GIPR agonist. - ASC48 demonstrated an EC50 of 1 pM in the hGIPR cAMP activation assay, exhibiting greater potency than tirzepatide (EC50 = 3 pM) and is a selective agonist for GIPR without activity for GLP-1R and GCGR. - ASC48 demonstra...

2026-07-15 18:00 2486

Kelun-Biotech and Harbour BioMed Announce NMPA Approval of IND Application for SKB575/HBM7575 for the Treatment of Asthma

CHENGDU, China, July 15, 2026 /PRNewswire/ -- Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. ("Kelun-Biotech" or the "Company", 6990.HK) and Harbour BioMed (HKEX: 02142) today announced thatthe National Medical Products Administration (NMPA) of China has approved the Investigational New Drug (...

2026-07-15 18:00 2293

World-renowned bioelectronics pioneer Prof. John Rogers to present second PAIR--Cambridge NeuroWorks online neuroscience seminar

HONG KONG, July 15, 2026 /PRNewswire/ -- The PolyU Academy for Interdisciplinary Research (PAIR) of The Hong Kong Polytechnic University has partnered with Cambridge NeuroWorks,  UK—an alliance of nine partners including the University of Cambridge—to launch an ...

2026-07-15 13:56 2699

Lynk Pharmaceuticals Announces Completion of Patient Enrollment in Phase III Clinical Trial of Zemprocitinib for Ankylosing Spondylitis

HANGZHOU, China and SHANGHAI and BOSTON, July 15, 2026 /PRNewswire/ -- Lynk Pharmaceuticals Co., Ltd. ("Lynk Pharmaceuticals"), a clinical-stage innovative drug development company focused on immune and inflammatory diseases, today announced that patient enrollment was completed on July 9 in the ...

2026-07-15 08:00 2999

Kelun-Biotech Announces Phase III Study of Sacituzumab Tirumotecan (sac-TMT) in Combination with Pembrolizumab as First-Line Treatment for PD-L1-Negative Non-Squamous NSCLC Met Primary Endpoint

* As a head-to-head Phase III trial comparing sac-TMT plus pembrolizumab with the first-line standard of care (immunotherapy plus chemotherapy), OptiTROP-Lung06 demonstrated the superiority of replacing conventional pemetrexed/platinum chemotherapy with sac-TMT, with significantly prolonged PFS...

2026-07-15 08:00 2907

NABR: The U.S. Fish and Wildlife Service for the Second Time Rejects Activists' Petition to List Long-Tailed Macaque Monkeys Under the Endangered Species Act

WASHINGTON, July 14, 2026 /PRNewswire/ -- On July 14, 2026, the U.S. Fish and Wildlife Service ("USFWS") for the second time declined to accept a petition filed by People for the Ethical Treatment of Animals ("PETA") and other activist groups to list long-tailed macaque ("LTM") monkeys (Macaca fa...

2026-07-14 23:37 3296
12345 ... 184